Evidence map›Paper›PMID 32396853›Full record

ArticleCancer cell2020

Bridging the Gap: The Impact of Genetic Ancestry on Routes to Tumorigenesis.

Chaitanya Bandlamudi, Barry S Taylor

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Chaitanya BandlamudiMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Barry S TaylorMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: taylorb@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
(PQ3) Integrative biomarkers of cancer progression and therapeutic response from germline and somatic clinical sequencingR01CA227534 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERGER, MICHAEL F. · 2019 to 2023
$3.5M
Defining the impact of mutant oncogene zygosityR01CA245069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2020 to 2024
$2.0M
Understanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0M
Targeting AKT-Mutant Human CancersR01CA207244 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2016 to 2020
$2.0M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA207244NCI NIH HHS R01 CA227534NCI NIH HHS R01 CA245069
6 · The paper itself

Abstract

Whether ancestry drives molecular differences that underlie disparities in cancer incidence and outcome is poorly understood. In this issue of Cancer Cell, Carrot-Zhang et al., through a rigorous analytical framework, explore ancestry-specific patterns of molecular alterations in cancers and demonstrate the need for novel strategies to address this formidable challenge.

Indexed as

Cell Transformation, NeoplasticNeoplasmsHumansIncidence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.